From wk 24 to wk 52 , inhibition of radiographic progression was maintained for ustekinumab-treated patients , and progression was substantially reduced among initial placebo recipients who started ustekinumab at wk 16 or wk 24 ( wk 24 - wk 52 , total vdH-S score mean change : 0.08 ) .